Infectious Diseases Market
Post-pandemic innovation in antivirals, AMR, and long-acting prophylactics
Market Overview
The infectious diseases market is evolving rapidly in the post-pandemic era, with renewed focus on antiviral development, antimicrobial resistance (AMR), long-acting prophylactics, and vaccine innovation. The market spans HIV, hepatitis, respiratory infections, fungal infections, and emerging pathogens. Novel approaches including long-acting injectables, broad-spectrum antivirals, and phage therapy are creating new opportunities while AMR remains a critical global health challenge.
Market Size Forecast (2024–2030)
Projected market value in USD billions
Market Segments
Share by therapeutic segment
Regional Market Analysis
Market share and growth by region
Key Drivers
- ▸Long-acting injectable antiretrovirals (cabotegravir, lenacapavir) transforming HIV treatment
- ▸Antimicrobial resistance (AMR) creating urgent need for novel antibiotics
- ▸mRNA vaccine platform expansion beyond COVID into RSV, influenza, and emerging pathogens
- ▸Hepatitis C elimination goals driving screening and treatment uptake
- ▸Post-pandemic preparedness investments in broad-spectrum antivirals
- ▸Long-acting prophylactics (PrEP) expanding HIV prevention market
Challenges
- ▸Antibiotic pricing economics discouraging investment in novel antibiotics
- ▸Generic competition eroding revenue in antiviral markets
- ▸Regulatory complexity for novel antimicrobial mechanisms
- ▸Payer resistance to premium pricing for antibiotics
- ▸Seasonal variability in respiratory infection markets
Opportunities
- ▸Long-acting HIV market projected to reach $10B+ by 2030
- ▸AMR market creating $5B+ opportunity with novel mechanism antibiotics
- ▸RSV market expansion with vaccines and long-acting monoclonal antibodies
- ▸Broad-spectrum antiviral platforms for pandemic preparedness
- ▸Phage therapy and microbiome-based approaches emerging
- ▸Hepatitis B functional cure pipeline with 50+ programs in development
Key Pipeline Drugs
Late-stage and recently approved therapies from Top 20 pharma
| Drug | Company | Phase |
|---|---|---|
Lenacapavir (Sunlenca) HIV treatment and PrEP | Gilead Sciences | Approved / Phase 3 (PrEP) |
Cabenuva (cabotegravir + rilpivirine) HIV treatment | ViiV Healthcare (GSK) | Approved / Phase 3 |
Ibrexafungerp (Brexafemme) Vaginal candidiasis, invasive candidiasis | SCYNEXIS | Approved / Phase 3 |
Zoliflodacin Gonorrhea (single-dose oral) | Entasis (Innoviva) | Phase 3 |
Murepavadin Pseudomonas aeruginosa infections | Polyphor (Spexis) | Phase 3 |
Bepirovirsen Chronic hepatitis B (functional cure) | GSK / Ionis | Phase 3 |
Nirsevimab (Beyfortus) RSV prevention in infants | Sanofi / AstraZeneca | Approved |
Clesrovimab RSV prevention in infants | Merck | Phase 3 |
Marketed Drugs — Current Landscape
Blockbuster and key marketed therapies shaping the competitive landscape
| Drug | Company | Annual Sales |
|---|---|---|
Biktarvy (bictegravir/emtricitabine/tenofovir) HIV market leader | Gilead Sciences | $12B+ |
Triumeq (dolutegravir/abacavir/lamivudine) Mature HIV regimen | ViiV Healthcare (GSK) | $3B+ |
Epclusa (sofosbuvir/velpatasvir) HCV market mature | Gilead Sciences | $2B+ (declining) |
Harvoni (sofosbuvir/ledipasvir) HCV mature, generics approaching | Gilead Sciences | $1B+ (declining) |
Tivicay (dolutegravir) HIV backbone component | ViiV Healthcare (GSK) | $2B+ |
Descovy (emtricitabine/tenofovir alafenamide) PrEP market leader | Gilead Sciences | $3B+ |
Veklury (remdesivir) COVID-19 antiviral standard | Gilead Sciences | $2B+ |
Paxlovid (nirmatrelvir/ritonavir) COVID-19 oral antiviral | Pfizer | $2B+ (declining) |
Competitive Landscape
Tiered analysis of companies shaping the infectious diseases market
Tier 1 — Infectious Disease Leaders
Dominant HIV, HCV, and respiratory infection franchises
Tier 2 — Specialty Infectious Disease
Strong positions in RSV, vaccines, and specific infectious disease segments
Tier 3 — Emerging Innovators
Novel approaches in antifungals, AMR, and broad-spectrum antivirals
Our Research Methodology
Infectious Disease KOL Network
35+ interviews with infectious disease specialists, HIV physicians, hepatologists, and public health experts across US, EU5, and APAC.
Epidemiology & Surveillance
Disease burden modeling using WHO, CDC, and national surveillance data with resistance pattern tracking for AMR analysis.
Pipeline Analytics
Tracking of 350+ infectious disease pipeline assets including novel antibiotics, long-acting antivirals, and vaccine platforms.
Payer & Access Analysis
Reimbursement analysis for infectious disease therapies with focus on antibiotic pricing models and PrEP coverage.
Pandemic Preparedness Assessment
Analysis of broad-spectrum antiviral platforms, vaccine manufacturing capacity, and government stockpiling strategies.
How We Help Clients Win in Infectious Diseases
Our consulting engagements combine deep therapeutic expertise with proprietary intelligence to identify where the opportunity lies — and how to capture it.
Long-Acting HIV Strategy
Position long-acting ARV therapies for market success in the evolving HIV treatment and PrEP landscape
AMR Market Entry
Navigate the complex AMR market with novel antibiotic development, regulatory strategy, and pull incentive optimization
RSV Market Strategy
Develop competitive strategies for RSV vaccines and long-acting monoclonal antibodies
HBV Functional Cure Strategy
Position HBV functional cure therapies for market entry with KOL engagement and payer access
Frequently Asked Questions
What is driving growth in the infectious diseases pharmaceutical market?
The infectious diseases market is driven by long-acting HIV therapies (lenacapavir, cabotegravir), RSV market expansion with vaccines and monoclonal antibodies, AMR creating urgent need for novel antibiotics, and post-pandemic investments in broad-spectrum antivirals and pandemic preparedness.
What is the opportunity in antimicrobial resistance (AMR)?
AMR represents a $5B+ opportunity as resistant pathogens create urgent need for novel mechanism antibiotics. However, the market faces challenges with antibiotic pricing economics. Pull incentives (subscription models, transferable exclusivity) are being implemented to encourage investment.
How can Medifirm help with infectious disease strategy?
We provide comprehensive infectious disease market intelligence including epidemiology and surveillance analysis, pipeline tracking, payer access strategy, AMR market entry planning, and pandemic preparedness assessment across HIV, hepatitis, respiratory infections, and AMR.